In vivo expression profile of the antiviral restriction factor and tumor-targeting antigen CD317/BST-2/HM1.24/tetherin in humans

Proceedings of the National Academy of Sciences of the United States of America

Volumn 108, Issue 33, 2011, Pages 13688-13693

  Erikson, Elin ^a   Adam, Tarek ^a,b   Schmidt, Sarah ^a   Lehmann Koch, Judith ^a   Over, Benjamin ^a   Goffinet, Christine ^a,c   Harter, Christoph ^a   Bekeredjian Ding, Isabelle ^a   Sertel, Serkan ^a   Lasitschka, Felix ^a   Keppler, Oliver T ^a  

^a UNIVERSITY OF HEIDELBERG   (Germany)

^b SAINT LOUIS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c UNIVERSITY HOSPITAL ULM   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIGEN; CD317 ANTIGEN; UNCLASSIFIED DRUG;

ANTIGEN EXPRESSION; ANTIGEN SPECIFICITY; ARTICLE; BONE MARROW; CELL TYPE; CONTROLLED STUDY; EPITHELIUM; GENE EXPRESSION PROFILING; HUMAN; HUMAN TISSUE; KIDNEY; LEYDIG CELL; LIVER CELL; LUNG ALVEOLUS CELL; MONOCYTE; PANCREAS; PANETH CELL; PLASMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; SALIVARY GLAND; STROMA CELL; TISSUE DISTRIBUTION; VASCULAR ENDOTHELIUM;

ANTIGENS, CD; ANTIGENS, NEOPLASM; ANTIVIRAL AGENTS; GPI-LINKED PROTEINS; HUMANS; IMMUNITY; INTERFERONS; PROTEIN ARRAY ANALYSIS; SPECIES SPECIFICITY; TISSUE ARRAY ANALYSIS; TISSUE DISTRIBUTION;

LASSA VIRUS;

EID: 80052012662     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1101684108     Document Type: Article

References (46)

1. Kupzig S., et al. (2003) Bst-2/HM1.24 is a raft-associated apical membrane protein with an unusual topology. Traffic 4:694-709. (Pubitemid 37168591)
2. Habermann A., et al. (2010) CD317/tetherin is enriched in the HIV-1 envelope and down-regulated from the plasma membrane upon virus infection. J Virol 84:4646-4658.
3. Neil S.J., Zang T., Bieniasz P.D. (2008) Tetherin inhibits retrovirus release and is antagonized by HIV-1 Vpu. Nature 451:425-430. (Pubitemid 351158893)
4. Van Damme N., et al. (2008) The interferon-induced protein BST-2 restricts HIV-1 release and is down-regulated from the cell surface by the viral Vpu protein. Cell Host Microbe 3:245-252. (Pubitemid 351494713)
5. Evans D.T., Serra-Moreno R., Singh R.K., Guatelli J.C. (2010) BST-2/tetherin: A new component of the innate immune response to enveloped viruses. Trends Microbiol 18:388-396.
6. Perez-Caballero D., et al. (2009) Tetherin inhibits HIV-1 release by directly tethering virions to cells. Cell 139:499-511.
7. Schubert H.L., et al. (2010) Structural and functional studies on the extracellular domain of BST2/tetherin in reduced and oxidized conformations. Proc Natl Acad Sci USA 107:17951-17956.
8. Yang H., et al. (2010) Structural insight into the mechanisms of enveloped virus tethering by tetherin. Proc Natl Acad Sci USA 107:18428-18432.
9. Goto T., et al. (1994) A novel membrane antigen selectively expressed on terminally differentiated human B cells. Blood 84:1922-1930. (Pubitemid 24286144)
10. Ozaki S., et al. (1999) Humanized anti-HM1.24 antibody mediates myeloma cell cytotoxicity that is enhanced by cytokine stimulation of effector cells. Blood 93:3922-3930. (Pubitemid 29249841)
11. Chiriva-Internati M., et al. (2003) Testing recombinant adeno-associated virus-gene loading of dendritic cells for generating potent cytotoxic T lymphocytes against a prototype self-antigen, multiple myeloma HM1.24. Blood 102:3100-3107. (Pubitemid 37314744)
12. Jalili A., et al. (2005) Induction of HM1.24 peptide-specific cytotoxic T lymphocytes by using peripheral-blood stem-cell harvests in patients with multiple myeloma. Blood 106:3538-3545. (Pubitemid 41609191)
13. Kawai S., et al. (2006) Construction of a conventional non-radioisotope method to quantify HM1.24 antigens: Correlation of HM1.24 levels and ADCC activity of the humanized antibody against HM1.24. Leuk Res 30:949-956. (Pubitemid 43841900)
14. Cheson B.D., Leonard J.P. (2008) Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma. N Engl J Med 359:613-626.
15. Kawai S., et al. (2006) Antitumor activity of humanized monoclonal antibody against HM1.24 antigen in human myeloma xenograft models. Oncol Rep 15:361-367.
16. Becker M., et al. (2005) Distinct gene expression patterns in a tamoxifen-sensitive human mammary carcinoma xenograft and its tamoxifen-resistant subline MaCa 3366/TAM. Mol Cancer Ther 4:151-168. (Pubitemid 40268073)
17. Cai D., et al. (2009) Up-regulation of bone marrow stromal protein 2 (BST2) in breast cancer with bone metastasis. BMC Cancer 9:102.
18. Kawai S., et al. (2008) Interferon-α enhances CD317 expression and the antitumor activity of anti-CD317 monoclonal antibody in renal cell carcinoma xenograft models. Cancer Sci 99:2461-2466.
19. Silveira N.J., et al.; Head and Neck Genome Project GENCAPO (2008) Searching for molecular markers in head and neck squamous cell carcinomas (HNSCC) by statistical and bioinformatic analysis of larynx-derived SAGE libraries. BMC Med Genomics 1:56.
20. Wang W., et al. (2009) HM1.24 (CD317) is a novel target against lung cancer for immunotherapy using anti-HM1.24 antibody. Cancer Immunol Immunother 58:967-976.
21. Goffinet C., et al. (2009) HIV-1 antagonism of CD317 is species-specific and involves Vpu-mediated proteasomal degradation of the restriction factor. Cell Host Microbe 5:285-297.
22. Allred D.C., et al. (1993) Association of p53 protein expression with tumor cell proliferation rate and clinical outcome in node-negative breast cancer. J Natl Cancer Inst 85:200-206. (Pubitemid 23046895)
23. Ishikawa J., et al. (1995) Molecular cloning and chromosomal mapping of a bone marrow stromal cell surface gene, BST2, that may be involved in pre-B-cell growth. Genomics 26:527-534.
24. Schaumann D.H., Tuischer J., Ebell W., Manz R.A., Lauster R. (2007) VCAM-1-positive stromal cells from human bone marrow producing cytokines for B lineage progenitors and for plasma cells: SDF-1, flt3L, and BAFF. Mol Immunol 44:1606-1612.
25. Swiecki M., Colonna M. (2010) Unraveling the functions of plasmacytoid dendritic cells during viral infections, autoimmunity, and tolerance. Immunol Rev 234:142-162.
26. Cao W., et al. (2009) Regulation of TLR7/9 responses in plasmacytoid dendritic cells by BST2 and ILT7 receptor interaction. J Exp Med 206:1603-1614.
27. Miyagi E., Andrew A.J., Kao S., Strebel K. (2009) Vpu enhances HIV-1 virus release in the absence of Bst-2 cell surface down-modulation and intracellular depletion. Proc Natl Acad Sci USA 106:2868-2873.
28. Ohtomo T., et al. (1999) Molecular cloning and characterization of a surface antigen preferentially overexpressed on multiple myeloma cells. Biochem Biophys Res Commun 258:583-591. (Pubitemid 29290312)
29. Haller O., Staeheli P., Kochs G. (2007) Interferon-induced Mx proteins in antiviral host defense. Biochimie 89:812-818. (Pubitemid 47001645)
30. Wenzel J., et al. (2005) Type I interferon-associated recruitment of cytotoxic lymphocytes: A common mechanism in regressive melanocytic lesions. Am J Clin Pathol 124:37-48. (Pubitemid 40944372)
31. Jekle A., et al. (2003) In vivo evolution of human immunodeficiency virus type 1 toward increased pathogenicity through CXCR4-mediated killing of uninfected CD4 T cells. J Virol 77:5846-5854. (Pubitemid 36538978)
32. Kirchhoff F. (2010) Immune evasion and counteraction of restriction factors by HIV-1 and other primate lentiviruses. Cell Host Microbe 8:55-67.
33. Serra-Moreno R., Jia B., Breed M., Alvarez X., Evans D.T. (2011) Compensatory changes in the cytoplasmic tail of gp41 confer resistance to tetherin/BST-2 in a pathogenic nef-deleted SIV. Cell Host Microbe 9:46-57.
34. Valbuena G., Walker D.H. (2006) The endothelium as a target for infections. Annu Rev Pathol 1:171-198.
35. Guarner J., Falcón-Escobedo R. (2009) Comparison of the pathology caused by H1N1, H5N1, and H3N2 influenza viruses. Arch Med Res 40:655-661.
36. Guo Y., Korteweg C., McNutt M.A., Gu J. (2008) Pathogenetic mechanisms of severe acute respiratory syndrome. Virus Res 133:4-12. (Pubitemid 351384649)
37. Johnson J.E., Gonzales R.A., Olson S.J., Wright P.F., Graham B.S. (2007) The histopathology of fatal untreated human respiratory syncytial virus infection. Mod Pathol 20:108-119. (Pubitemid 44967956)
38. Yondola M.A., et al. (2011) Budding capability of the influenza virus neuraminidase can be modulated by tetherin. J Virol 85:2480-2491.
39. Coleman C.M., Wu L. (2009) HIV interactions with monocytes and dendritic cells: Viral latency and reservoirs. Retrovirology 6:51.
40. Jacquelin B., et al. (2009) Nonpathogenic SIV infection of African green monkeys induces a strong but rapidly controlled type I IFN response. J Clin Invest 119:3544-3555.
41. Towers G.J. (2007) The control of viral infection by tripartite motif proteins and cyclophilin A. Retrovirology 4:40.
42. Goila-Gaur R., Strebel K. (2008) HIV-1 Vif, APOBEC, and intrinsic immunity. Retrovirology 5:51.
43. Jeon Y.J., Yoo H.M., Chung C.H. (2010) ISG15 and immune diseases. Biochim Biophys Acta 1802:485-496.
44. Greenwell-Wild T., et al. (2009) Interleukin-27 inhibition of HIV-1 involves an intermediate induction of type I interferon. Blood 114:1864-1874.
45. Rollason R., Korolchuk V., Hamilton C., Jepson M., Banting G. (2009) A CD317/tetherin-RICH2 complex plays a critical role in the organization of the subapical actin cytoskeleton in polarized epithelial cells. J Cell Biol 184:721-736.
46. Oldham-Ott C.K., Gilloteaux J. (1997) Comparative morphology of the gallbladder and biliary tract in vertebrates: Variation in structure, homology in function and gallstones. Microsc Res Tech 38:571-597. (Pubitemid 27426382)